Protagonist Therapeutics (PTGX) Stock: Buy, Sell, or Hold?
PTGX - Protagonist Therapeutics, Inc
$139.19
-1.70 (-1.21%)
▼
5d:
+1.35%
30d:
-4.98%
90d:
+5.75%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PTGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PTGX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PTGX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: PTGX is currently trading at $139.19, which is considered oversold relative to its 30-day fair value range of $141.16 to $148.98. From a valuation perspective, the stock is trading at a discount (Forward PE: -698.7) compared to its historical average (83.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PTGX is in a strong uptrend. Immediate support is located at $134.10, while resistance sits at $147.71.
Market Sentiment: PTGX scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $174.69 (+25.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PTGX is in a strong uptrend. Immediate support is located at $134.10, while resistance sits at $147.71.
Market Sentiment: PTGX scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $174.69 (+25.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$141.16 -
$148.98
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
96.2%
Protect Your Profits
Holding PTGX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (69/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.5% below Wall St target ($174.69)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 17% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$141.16 -
$148.98
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$8.76
(6.3%)
Support & Resistance Levels
Support Level
$134.10
Resistance Level
$147.71
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-698.74
Wall Street Target
$174.69
(+25.5%)
Revenue Growth (YoY)
3749.2%
Earnings Growth (YoY)
351.3%
Profit Margin
29.4%
PE vs Historical
-698.7 vs 83.6
CHEAP
Share & Embed Analysis
Last updated: October 02, 2026 7:04 AM ET
Data refreshes hourly during market hours. Next update: 8:04 AM
Data refreshes hourly during market hours. Next update: 8:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Asif Ali
SELL
1750 shares
2026-04-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
Advanced PTGX Option Strategies
Professional options setups generated by AI based on today's PTGX price and gamma walls.
